More articles from Volume 30, Issue 2, 2014
Uticaj kvaliteta ishrane na simptome donjih partija urotrakta
Trisomy 13 detection in the first trimester of pregnancy using a chromosome‐selective cell‐free <scp>DNA</scp> analysis method
PRIKAZI SLUČAJA CASE REPORTS
Pseudocyst of the spleen-report of two cases
Magnetic resonance imaging
Article views
Cancer stem cells -current concepts, therapeutic implications and challenges
,
Krstic Miljan
Stojnev Slavica
Published: 01.12.2013.
Biochemistry
Volume 30, Issue 2 (2014)
pp. 1140-1146;
Abstract
Keywords
References
1.
Medema J. Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013;(4):338–44.
2.
Tang D. Understanding cancer stem cell heterogeneity and plasticity. Cell Research. 2012;457–72.
3.
Stojnev S, Krstic M, Ristic-Petrovic A, Stefanovic V, Hattori T. Gastric cancer stem cells: therapeutic targets. Gastric Cancer. 2014;(1):13–25.
4.
Jordan C, Guzman M, Noble M. Cancer stem cells. N Engl J Med. 2006;(12):1253–61.
5.
Panyam J. Cancer stem cells. Drug Deliv Transl Res. 2013;111–2.
6.
Welte Y, Adjaye J, Lehrach H, Regenbrecht C. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal. 2010;(1):6.
7.
Magee J, Piskounova E, Morrison S. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;(3):283–96.
8.
Houghton J, Stoicov C, Nomura S, Rogers A, Carlson J, Li H. Gastric cancer originating from bone marrowderived cells. Science. 2004;(5701):1568–71.
9.
Lu X, Kang Y. Cell fusion as a hidden force in tumor progression. Cancer Research. 2009;(22):8536–9.
10.
Li, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res. 2012;(3):576–80.
11.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;(4):663–76.
12.
Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;(3):281–93.
13.
Yang L, Ping Y, Yu X, Qian F, Guo Z, Qian C. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett. 2011;(1):46–52.
14.
Borovski T, Sousa E Melo D, Vermeulen F, Medema L, J. Cancer stem cell niche: the place to be. Cancer Res. 2011;(3):634–9.
15.
Cabarcas S, Mathews L, Farrar W. The cancer stem cell niche -there goes the neighborhood? Int J Cancer. 2011;(10):2315–27.
16.
Van Der Horst E, Chinn L, Wang M, Velilla T, Tran H, Madrona Y. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 2009;(4):355–64.
17.
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci. 2009;(38):16281–6.
18.
Smith L, Nesterova A, Ryan M, Duniho S, Anderson J, M. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;(1):100–9.
19.
Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;(18):5821–8.
20.
Lathia J, Hitomi M, Gallagher J, Gadani S, Adkins J, Vasanji A. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011;
21.
Swaminathan S, Roger E, Toti U, Niu L, Ohlfest J, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 2013;(3):280–7.
22.
Andrews T, Wang D, Harki D. Cell surface markers of cancer stem cell: diagnostic macromolecules and targets for drug delivery. Drug Deliv Transl Res. 2013;121–42.
23.
Wakamatsu Y, Sakamoto N, Oo H, Naito Y, Uraoka N, Anami K. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int. 2012;(2):112–9.
24.
Joshua B, Kaplan M, Doweck I, Pai R, Weissman I, Prince M. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck. 2012;(1):42–9.
25.
Ucar D, Cogle C, Zucali J, Ostmark B, Scott E, Zori R. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact. 2009;(1–3):48–55.
26.
Zhi Q, Chen X, Ji J, Zhang J, Li J, Cai Q. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011;(7):509–15.
27.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;(6464):645–8.
28.
Al-Hajj M, Wicha M, Hernandez B, Morrison A, Clarke S, M. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;(7):3983–8.
29.
Neumeister V, Agarwal S, Bordeaux J, Camp R, Rimm D. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010;(5):2131–8.
30.
Zhang S, Schafer-Hales K, Khuri F, Zhou W, Vertino P, Marcus A. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res. 2008;(3):740–8.
31.
Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek P, Chang H. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci. 2010;(44):18874–9.
32.
Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003;(8):1454–63.
33.
Cruz F, Matushansky I. Solid tumor differentiation therapy -is it possible. Oncotarget. 2012;559–67.
34.
Piccirillo S, Reynolds B, Zanetti N, Lamorte G, Binda E, Broggi G. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (Lond). 2006;761–5.
35.
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;(12):751–60.
36.
Lambert J. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;543–9.
37.
Chari R. Targeted cancer therapy: conferring specificity to cytotoxic drugs. ACC Chem Res. 2008;98–107.
38.
Scott A, Tebbutt N, Lee F, Cavicchiolo T, Liu Z, Gill S. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res. 2007;3286–92.
39.
Smith L, Nesterova A, Ryan M, Duniho S, Anderson J, M. CD133/prominin-1 is a potential therapeutic target for antibody -drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;100–9.
40.
Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol. 2007;(1):61–4.
41.
Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget. 2011;(12):1291–301.
42.
Yilmaz O, Valdez R, Theisen B, Guo W, Ferguson D, Wu H. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;(7092):475–82.
43.
Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li Y. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;(15):7445–52.
44.
Han M, Kim G, Moon S, Kim W, Nam T, Choi Y. Apoptosis induction by glycoprotein isolated from Laminaria japonica is associated with down-regulation of telomerase activity and prostaglandin E2 synthesis in AGS human gastric cancer cells. Int J Oncol. 2011;577–84.
45.
Hirsch H, Iliopoulos D, Tsichlis P, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;(19):7507–11.
46.
Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One. 2011;(9):24397.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
